Polyrizon Ltd Stock Price, News & Analysis

Polyrizon (Nasdaq: PLRZ) announced positive pre-clinical results for its intranasal formulation PL-14 on October 6, 2025. The study measured penetration of the house dust mite allergen Der p 1 through a PL-14 hydrogel barrier.

Key measured results: 1.07% penetration at 1 hour, 1.14% at 2 hours and 13.6% at 4 hours. The study used allergen loads described as tens of times higher than typical real-world exposures. Polyrizon said PL-14 formed an effective nasal barrier and plans to initiate clinical studies to support regulatory and clinical pathways.

Polyrizon (NASDAQ:PLRZ) has submitted a pre-submission package to the FDA for its PL-14 Allergy Blocker, marking a significant regulatory milestone. The novel nasal spray creates a physical barrier to block allergens and provide relief from allergic rhinitis symptoms.

The comprehensive submission includes manufacturing plans, clinical development strategies, and regulatory pathways. PL-14 is designed to alleviate mild nasal irritation symptoms caused by various airborne allergens, including environmental pollens, house dust, animal hairs, and dust mites.

Polyrizon (NASDAQ:PLRZ) has reported successful preclinical results for its PL-14 Allergy Blocker, demonstrating over 60% deposition in the nasal vestibule. The study, conducted with the University of Parma, validated the product's targeted delivery mechanism using a silicone-based human nasal cast and fluorescein-labeled imaging.

The PL-14 formulation, part of Polyrizon's proprietary Capture & Contain (C&C) platform, aims to create a physical barrier against allergens before they trigger immune responses. The global allergen blocker market, valued at $0.14 billion in 2024, is projected to reach $0.21 billion by 2033, growing at a 4.4% CAGR.

Polyrizon (Nasdaq: PLRZ), a biotechnology company focused on intranasal product development, has successfully regained compliance with all Nasdaq listing requirements. The company received formal confirmation from the Nasdaq Hearings Panel's Hearings Advisor on August 13, 2025, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

The confirmation satisfies all previously outlined conditions by the Nasdaq Hearings Panel in their July 9, 2025 decision. As a result, Polyrizon will maintain its listing and continue trading on the Nasdaq Capital Market under the ticker symbol "PLRZ".

Polyrizon (Nasdaq: PLRZ) has announced positive preclinical results for its PL-14 Allergy Blocker, demonstrating successful intranasal delivery in a collaborative study with the University of Parma. The study showed over 60% deposition of the product in the nasal vestibule, the critical first point of contact for airborne allergens.

The research validates the company's proprietary Capture & Contain (C&C) platform, supporting its mechanism of action as a physical barrier against allergens. The global allergen blocker market, valued at $0.14 billion in 2024, is projected to reach $0.21 billion by 2033, growing at a 4.4% CAGR. The company plans to advance toward clinical trials following these encouraging preclinical results.

Polyrizon (Nasdaq: PLRZ) has successfully retained its Nasdaq listing following a hearing with the Nasdaq Hearings Panel. The company faced potential delisting concerns related to a private placement involving 5,962,073 ordinary shares, including 5,829,389 shares issued through warrant exercises. The Panel granted continued listing subject to meeting the Minimum Bid Price Rule by October 17, 2025.

Following the private placement, Polyrizon reports a cash balance of $15.68 million. The company has committed to avoiding complex financing instruments and is implementing enhanced internal controls for securities issuances and Nasdaq compliance.

Polyrizon (NASDAQ: PLRZ) has announced promising preclinical results for its hydrogel-based Trap & Target (T&T) platform for intranasal drug delivery. In collaboration with the University of Parma, the study demonstrated that the company's hydrogel formulation successfully achieved over 60% targeted deposition in the middle and upper turbinates of the nasal cavity, which is crucial for central nervous system (CNS) drug delivery. The technology shows potential for treating CNS conditions like opioid overdose and epileptic seizures where rapid brain access is critical. The study utilized a silicone-based human nasal cast and fluorescein-traced imaging to validate the delivery system's effectiveness. Polyrizon plans to continue validation through animal models and initiate safety studies as part of its development roadmap.

Polyrizon Ltd. (PLRZ) has received a delisting notification from Nasdaq's Listing Qualifications Department due to concerns over a recent securities issuance. The notification stems from the company's March 31, 2025 securities purchase agreement, specifically regarding Series A warrants with alternate cashless exercise provisions that Nasdaq determined could cause substantial shareholder dilution.

While the notice doesn't result in immediate delisting of PLRZ shares from the Nasdaq Capital Market, the company must request a hearing before a Hearings Panel to maintain its listing. Polyrizon has confirmed its intention to request this hearing, which will automatically stay any suspension or delisting actions pending the hearing's outcome and any additional extension period granted by the Panel.

Polyrizon (NASDAQ: PLRZ) has announced positive preclinical results for its intranasal hydrogel platform. The ex vivo studies, conducted in collaboration with Prof. Fabio Sonvico's laboratory using rabbit nasal mucosa, demonstrated two key technological achievements: strong mucoadhesion and extensive nasal surface coverage. Using two-photon fluorescence microscopy, researchers observed that the formulation spreads rapidly and uniformly across nasal tissues, forming a consistent surface layer. The tests also showed that the formulation maintains strong attachment to nasal tissue even under simulated physiological nasal fluid flow conditions. These properties are crucial for providing effective protection against airborne biological threats and enabling efficient intranasal therapeutic delivery.